Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218465 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
NCT00218465: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00218465 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 264 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218465, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of the glycine antagonist, GW468816, compared with placebo on duration of abstinence and rates of relapse in recently quit female smokers in a randomized, double-blind, five-week clinical trial. According to the investigators, the new medication, GW468816, is thought to send certain signals in the brain that may be effective in helping people stay abstinent after they have recently quit smoking. GW468816 is a non-nicotine drug. The investigators of this study hypothesize that subjects receiving GW468816 will demonstrate a significantly longer time to relapse to smoking than those in the placebo group, as measured by the primary outcome measure (see below).
Interventions
- DRUG Placebo Comparator: Placebo
- DRUG GW468816
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218465
The ClinicalTrials.gov registry entry for NCT00218465 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator: Placebo is the first listed.
NCT00218465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218465 about?
NCT00218465 is a clinical study titled "Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking". The purpose of this study is to evaluate the efficacy of the glycine antagonist, GW468816, compared with placebo on duration of abstinence and rates of relapse in recently quit female smokers in a randomized, double-blind, five-week clinical trial. According to the investigators, the new medication...
What is the current status of trial NCT00218465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2006-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00218465?
The interventions under investigation include: Placebo Comparator: Placebo (DRUG), GW468816 (DRUG).
Who is sponsoring clinical trial NCT00218465?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.